Validity verdict (step 6)
approved, checked. Reconstruction: premise is the urinary TMAO dose series (236/433/634/944/900 umol/24h at 0/1/2/4/6 yolks) with a flat, statistically indistinguishable 4→6 interval; conclusion is a concave, saturating exposure-response that bounds/shapes TMAO from high egg intake. Traced the arithmetic: per-yolk increments run ~197 (0→1), ~201 (1→2), ~155/yolk (2→4), then ~-22/yolk (4→6). The fall in marginal increment to ≈0 is directly in the numbers — concavity does not need extra assumptions, so the “saturating dose-response / incremental TMAO falls at high intake” content is checked and holds. Considered the undercutting defeater that a urinary plateau could reflect saturation of renal excretion rather than of production, in which case plasma (harm-relevant) TMAO could keep rising while urine flattens, breaking “bounds exposure.” Judged it non-surviving under charity: in healthy young subjects at these modest TMAO levels renal TMAO clearance is not near saturation, so urinary output tracks exposure — a reasonable premise, not completion-by-force. The statement’s hedges (“indicate,” attributing to “conversion capacity” while the body allows gut-TMA and/or FMO3) keep it within what the data license; the mechanism attribution is the softest part but does not affect the exposure-bounding conclusion, which holds whichever step saturates. Scope note honored: bounds/shapes exposure, does not confirm or deny harm.
The urinary TMAO series (236, 433, 634, 944, 900 umol/24h for 0/1/2/4/6 yolks) is not linear: the marginal increment falls from ~200 umol per yolk over the 0-4 range to essentially zero (944 vs 900) between 4 and 6 yolks, and the 4- and 6-yolk responses are statistically indistinguishable. A plateau at high substrate load is the signature of a rate-limited step reaching capacity — here the gut-microbial trimethylamine production and/or hepatic FMO3 oxidation. Two consequences follow. First, the exposure-response of TMAO to egg intake is concave: doubling eggs from 3 to 6 does not double TMAO, so the incremental TMAO risk (if any) of very high egg intake is smaller than a linear extrapolation from low doses would predict. Second, the ~2-yolk threshold means a single egg produces no detectable TMAO signal, so any TMAO-mediated risk would concentrate at higher per-meal doses. This bounds and shapes the exposure side of the TMAO-harm hypothesis rather than confirming or denying harm itself.